In experimental colitis, histologic damage and immune activation were aggravated and changes to the microbiota more pronounced in the absence of GAL3R. Thus, this study identifies activation of GAL3R signaling as a possible target for new treatment strategies to combat IBD. Here, GALR3 is linked to inflammatory bowel disease.